Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $51.60.
據MarketBeat報道,Arcutis BioTreateutics,Inc.(納斯達克代碼:ARQT-GET評級)已收到目前覆蓋該股的六家研究公司的共識評級為買入。六位股票研究分析師已將該股評級為買入建議。在去年發佈了一份股票報告的分析師中,平均一年的價格目標是51.60美元。
Separately, Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $49.00 to $51.00 and gave the stock an "overweight" rating in a report on Tuesday, December 13th.
另外,摩根士丹利在12月13日(星期二)的一份報告中將Arcutis BioTreateutics的目標價從49.00美元上調至51.00美元,並給予該股“增持”評級。
Insiders Place Their Bets
內部人士下注
In other news, Director Howard G. Welgus sold 8,500 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $13.72, for a total value of $116,620.00. Following the completion of the transaction, the director now owns 165,825 shares in the company, valued at approximately $2,275,119. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Masaru Matsuda sold 1,720 shares of the business's stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $18.19, for a total transaction of $31,286.80. Following the completion of the transaction, the insider now owns 19,535 shares in the company, valued at approximately $355,341.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Howard G. Welgus sold 8,500 shares of the business's stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $13.72, for a total value of $116,620.00. Following the transaction, the director now owns 165,825 shares of the company's stock, valued at approximately $2,275,119. The disclosure for this sale can be found here. Insiders have sold 13,695 shares of company stock worth $205,107 in the last three months. 23.00% of the stock is owned by insiders.
在其他新聞方面,董事霍華德·G·韋爾格斯在1月17日(星期二)的一筆交易中出售了8,500股Arcutis BioTreateutics的股票。這隻股票的平均售價為13.72美元,總價值為116,620.00美元。交易完成後,董事現在擁有該公司165,825股票,價值約2,275,119美元。這筆交易是在提交給美國證券交易委員會的法律文件中披露的,該文件可通過此超鏈接。在相關新聞中,內部人士松田正郎在11月21日星期一的一次交易中出售了1,720股該公司的股票。該股以18.19美元的平均價格出售,總成交金額為31286.80美元。交易完成後,這位內部人士現在擁有該公司19,535股,價值約355,341.65美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在美國證券交易委員會網站。此外,董事霍華德·G·韋爾格斯在1月17日(星期二)的一筆交易中出售了8,500股該公司的股票。這些股票的平均價格為13.72美元,總價值為116,620.00美元。交易完成後,董事現在擁有該公司165,825股股票,價值約2275,119美元。關於這次銷售的披露可以找到這裏。在過去的三個月裏,內部人士已經出售了13,695股公司股票,價值205,107美元。23.00%的股份由內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
Arcutis Biotherapeutics Stock Performance
Arcutis BioTreateutics股票表現
Shares of NASDAQ:ARQT opened at $16.67 on Friday. The company has a market cap of $1.02 billion, a P/E ratio of -2.83 and a beta of 0.52. The company has a debt-to-equity ratio of 0.73, a quick ratio of 13.27 and a current ratio of 13.39. Arcutis Biotherapeutics has a one year low of $12.81 and a one year high of $27.40. The business's 50-day simple moving average is $15.62 and its 200 day simple moving average is $18.92.
納斯達克:ARQT週五開盤報16.67美元。該公司市值為10.2億美元,市盈率為-2.83,貝塔係數為0.52。該公司的負債權益比率為0.73,速動比率為13.27,流動比率為13.39。Arcutis BioTreateutics的一年低點為12.81美元,一年高位為27.40美元。該業務的50日簡單移動均線切入位為15.62美元,200日簡單移動均線切入位為18.92美元。
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.35). The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.01 million. On average, sell-side analysts forecast that Arcutis Biotherapeutics will post -5.96 earnings per share for the current fiscal year.
Arcutis BioTreateutics(納斯達克:ARQT-GET評級)最近一次公佈收益業績是在11月8日(星期二)。該公司公佈本季度每股收益(1.89美元),低於普遍預期的(1.54美元)和(0.35美元)。該公司本季度營收為73萬美元,而分析師預期為101萬美元。賣方分析師平均預測,Arcutis BioTreateutics本財年每股收益將達到5.96美元。
About Arcutis Biotherapeutics
關於Arcutis生物療法
(Get Rating)
(獲取評級)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Arcutis BioTreateutics,Inc.是一家生物製藥公司,專注於皮膚病治療方法的開發和商業化。它的主要候選產品是ARQ-151,這是一種外用羅氟司特乳膏,已經完成了治療斑塊型牛皮癬和特應性皮炎的第三階段臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Arcutis Biotherapeutics (ARQT)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免費獲取StockNews.com關於弓狀生物療法(ARQT)的研究報告
- 市場回顧周-1/30-2/3
- 細價股值得嗎?你應該投資細價股嗎?
- Zimmer Biomet盈利節節攀升,增長可能被計入價格
- 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Arcutis BioTreatetics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Arcutis BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。